MetCool ACS- Metformin Cooling Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

Also called NCT05305898

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose other
Phase
Phase 3
Enrolled
  • 2,000 participants (planned count) (from the registry)
Sponsor
Military Institute od Medicine National Research Institute (from the registry)
Registry
  • NCT NCT05305898
  • EudraCT 2020-004962-21
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05305898. Randomized; no masking; primary purpose other. Start 2022-02-08 (actual); primary completion 2025-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
"MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
Condition
Acute Coronary Syndrome
Intervention (Drug)
Metformin
Lead sponsor
Military Institute od Medicine National Research Institute (class: other)
Collaborator
ABM Industries (class: other)

Record details

Record id
cardio:ct-nct05305898
Content hash
719171bd1568e6388b51e8c9945a09b255b531c071df3c34b96c2c7579b7e756